Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Prostate biopsy in Western Australia 1998–2004

Abstract

We reviewed the status of prostate cancer diagnosis in Western Australia (WA) with the aim of improving decision-making about PSA testing and prostate biopsy. Our patient cohort was 5145 men undergoing an initial biopsy for prostate cancer diagnosis in WA between 1998 and 2004. Transrectal ultrasound-guided biopsies were performed by one of 18 clinicians whereas all pathology was assessed by one urological pathologist. Cancer detection rates were 59% for initial biopsies and 32% for repeat biopsies. High-grade cancer (Gleason sum 7) accounted for 69 and 38% of tumours diagnosed on initial and repeat biopsy, respectively. The rates of cancer diagnosis and detection of high-grade tumours were both 1.6-fold higher in WA patients compared with those obtained at baseline screening of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial of US men (P<0.001). These higher than expected rates of cancer detection and high histological grade indicate that urological practice in WA between 1998 and 2004 was significantly more conservative than US practice over this time period, probably leading to underdiagnosis of prostate cancer. Our findings may be relevant to other countries where urological practice differs from that in the United States.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Urological Society of Australia and New Zealand. PSA testing policy 2009 2009. Available at: http://www.usanz.org.au/uploads/29168/ufiles/USANZ_2009_PSA_Testing_Policy_Final1.pdf. Accessed November 2009.

  2. American Urological Association, Education and Research Inc. Prostate-specific antigen best practice statement: 2009 Update 2009. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf. Accessed November 2009.

  3. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schröder FH, Hugosson J, Roobol MJ, Tamella TLJ, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a rancomized European study. N Engl J Med 2009; 360: 1320–1328.

    Article  PubMed  Google Scholar 

  5. Bastian PJ, Mangold LA, Epstein JI, Partin AW . Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004; 101: 2001–2005.

    Article  PubMed  Google Scholar 

  6. Epstein JI, Walsh PC, Carmichael M, Brendler CB . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368–374.

    Article  CAS  PubMed  Google Scholar 

  7. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433–438.

    Article  PubMed  Google Scholar 

  8. Slevin TJ, Donnelly N, Clarkson JP, English DR, Ward JE . Prostate cancer testing: behaviour, motivation and attitudes among Western Australian men. Med J Aust 1999; 171: 185–188.

    Article  CAS  PubMed  Google Scholar 

  9. Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Agius PA et al. Men in Australia telephone survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2006; 366: 218–224.

    Article  Google Scholar 

  10. Postma R, Shröder FH, van Leenders GJLH, Hoedemaeker RF, Vis AN, Roobol MJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)—section Rotterdam: a comparison of two rounds of screening. Eur Urol 2007; 52: 89–97.

    Article  PubMed  Google Scholar 

  11. Allsbrook Jr WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI . Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologists. Hum Pathol 2001; 32: 81–88.

    Article  PubMed  Google Scholar 

  12. Presti Jr JC . Prostate biopsy strategies. Nat Clin Pract Urol 2007; 4: 505–511.

    Article  PubMed  Google Scholar 

  13. Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC . Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22: 7–10.

    Article  PubMed  Google Scholar 

  14. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A . Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urologic practice. BJU Int 2005; 95: 545–548.

    Article  PubMed  Google Scholar 

  15. Stapleton AMF, Johns RL, Kopsaftis T, Tamblyn J . Abnormal PSA tests: delays in referral. Aust Fam Physician 2008; 37: 84–88.

    PubMed  Google Scholar 

  16. O'Dowd GJ, Miller MC, Orozco R, Veltri RW . Analysis of repeated biopsy results within one year after a noncancer diagnosis. Urology 2000; 55: 553–559.

    Article  CAS  PubMed  Google Scholar 

  17. Lowe FC, Gilbert SM, Kahane H . Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324 684 biopsies performed between 1995 and 2002. Urology 2003; 62: 1045–1049.

    Article  PubMed  Google Scholar 

  18. Maffezzini M, Gavazzi L, Calcagno T, Capponi G, Bandelloni R . Still a place for the classical systematic sextant technique? Cancer detection rates and complications in 1025 consecutive prostatic biopsies. Arch Ital Urol Androl 2005; 77: 106–108.

    PubMed  Google Scholar 

  19. Lienert AR, Davidson PJ, Wells JE . The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population. NZMJ 2009; 122: 39–50.

    Google Scholar 

  20. Newell KJ, Amrhein JF, Desai RJ, Middlebrook PF, Webster TM, Sawka BW et al. Prostate gland biopsies and prostatectomies: an Ontario community hospital experience. Can Urol Assoc J 2008; 2: 518–523.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Scales Jr CD, Antonelli J, Curtis LH, Schulman KA, Moul JW . Prostate-specific antigen screening among young men in the United States. Cancer 2008; 113: 1315–1323.

    Article  PubMed  Google Scholar 

  22. Beulac JA, Fry RN, Onysko J . Lifetime and recent prostate-specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006; 97: 171–176.

    Google Scholar 

  23. Zappa M, Visioli C, Crocetti E, Buonamici C, Baccini A, Taddei S et al. Practice of opportunistic PSA screening in the Florence district. Eur J Cancer Prev 2003; 12: 201–204.

    Article  CAS  PubMed  Google Scholar 

  24. Ciatto S, Houssami N, Martinelli F, Giusti F, Zappa M . PSA use and incidence of prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects with PSA elevation? Tumori 2008; 94: 518–522.

    Article  PubMed  Google Scholar 

  25. Sneyd MJ, Cox B, Paul C, Skegg CG . PSA testing and digital rectal examination in New Zealand. Aust NZ J Public Health 2003; 27: 502–506.

    Article  Google Scholar 

  26. Gibbons L, Waters C . Prostate cancer—testing, incidence, surgery and mortality. Health Rep 2003; 14: 9–20.

    PubMed  Google Scholar 

  27. Grubb III RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: 1524–1530.

    Article  PubMed  Google Scholar 

  28. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584–591.

    Article  PubMed  Google Scholar 

  29. Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A . Extent of prostate-specific antigen contamination in the Spanish section of the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2006; 50: 1234–1240.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The West Australian Prostate Biopsy Database and Abbott-West Australian Radical Prostatectomy Databases are supported by the Prostate Cancer Foundation of Australia and Abbott Australasia.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R J Cohen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Brien, B., Brown, A., Shannon, T. et al. Prostate biopsy in Western Australia 1998–2004. Prostate Cancer Prostatic Dis 13, 263–269 (2010). https://doi.org/10.1038/pcan.2010.7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2010.7

Keywords

Search

Quick links